CASE REPORT

Survival of a Patient With Tetanus in Bhutan Using a Magnesium Infusion Managed Only by Clinical Signs

Kuenza P. Wangmo, MD; Margie Teng, MD; Richard Henker, PhD, CRNA; Stephen Kinnear, MBBS; Jampel Tshering, MD; Nancy E. Wang, MD

From the Department of Anaesthesiology, Jigme Dorji Wangchuck National Referral Hospital, Thimphu, Bhutan (Drs Wangmo and Tshering); Division of Emergency Medicine, Department of Surgery, Stanford University School of Medicine, Stanford, CA (Drs Teng and Wang); School of Nursing, University of Pittsburgh, Pittsburgh, PA (Dr Henker); and the Flinders Medical Centre, Bedford Park, South Australia (Dr Kinnear).

Tetanus is a life-threatening disease that continues to have a high prevalence in developing countries. Severe muscle spasms often require patients to receive tracheostomy, high-dose sedatives, and sometimes prolonged neuromuscular blockade. Magnesium sulfate (MgSO_4) infusion has great promise as an adjunct treatment for severe tetanus, as it may allow clinicians to decrease the dose of other sedative medications. Although the mechanism of action of MgSO_4 is not well understood, it appears to attenuate both the muscle spasms and autonomic instability associated with severe tetanus infections. However, MgSO_4 infusions are often managed based on serial measurements of serum magnesium levels and other laboratory tests such as arterial blood gases, which can be difficult to obtain in resource-poor settings. We describe a case of severe tetanus in Bhutan managed through the use of magnesium infusion titrated solely to physical examination findings.

Key words: anticonvulsants, Bhutan, developing countries, magnesium sulfate, autonomic nervous system diseases, tetanus

Introduction

Tetanus is a life-threatening disease and is difficult to manage even in environments with the best resources available. Severe muscle spasms often require patients to receive tracheostomy, high-dose sedatives, and sometimes prolonged neuromuscular blockade. Magnesium sulfate (MgSO_4) infusion has great promise as an adjunct treatment of severe tetanus, as it may allow clinicians to decrease the dose of other sedative medications. Typically, MgSO_4 infusions are managed based on serial measurements of magnesium levels and other laboratory values. We describe a case of tetanus management in Bhutan through the use of magnesium infusion titrated solely to physical examination findings.

Case Report

A 56-year-old man was admitted to Wangdue Hospital, a small district hospital in Bhutan, 2 weeks after sustaining an injury to his left thigh. The patient had no history of

receiving a tetanus vaccine. At the district hospital, the patient had the typical risus sardonicus facies, fever, and whole body spasms. He was treated with antitetanus serum based on the clinical diagnosis of tetanus infection. Seven days later, worsening clinical status prompted transfer of the patient to Jigme Dorji Wangchuck National Referral Hospital (JDWNRH) in Thimphu, Bhutan.

On admission to JDWNRH, the patient was experiencing severe spasms of all voluntary muscles with minimal provocation. He was febrile to 38.3°C and mildly tachycardic. His mentation was intact. Initial treatment included intravenous antibiotics and benzodiazepines. The severity of rigidity and spasms continued to increase, despite increased use of benzodiazepines. A tracheostomy was performed and the patient required mechanical ventilation as a result of respiratory distress. The patient experienced worsening muscle spasms refractory to medications such as atracurium, morphine, and diazepam. At one point, the patient received 80 mg of diazepam during 24 hours. Owing to the refractory nature of the spasms and the large amount of sedatives that were required, the decision was made to use MgSO_4 infusion as first-line therapy on hospital day 14.

Corresponding author: Nancy E. Wang, MD, Stanford University Medical School, 300 Pasteur Drive, Alway M121, Mail Code 5119, Stanford, CA 94305 (e-mail: ewen@stanford.edu).

The use of magnesium infusion for treatment for tetanus had not been attempted in this hospital previously. JDWNRH lacks the ability to perform serum magnesium levels and arterial blood gas measurements. However, the hospital has used intravenous MgSO_4 to treat eclampsia by monitoring for clinical signs and symptoms of magnesium toxicity. The patient was started on IV MgSO_4 therapy according to a previously published protocol (Appendix).¹ The patient received a loading dose of 70 mg/kg IV MgSO_4 and then was started on a maintenance infusion of 2 g/h. The MgSO_4 infusion was titrated to control spasms and rigidity while monitoring vital signs, sedation, and deep tendon reflexes. All other sedative drugs were ceased. Urine output was monitored on an hourly basis.

After being placed on the magnesium infusion, the patient's spasms decreased. Within 3 days, the patient was receiving MgSO_4 as the sole treatment for his tetanus. Before the use of magnesium, examiners had not been able to passively flex the patient's knees. However, after initiation of MgSO_4 , the patient's rigidity decreased substantially and the patient could independently flex his lower limbs. The rate of magnesium infusion was titrated to the patient's spasms with close observation of vital signs and sedation. After 8 days of treatment, the infusion dosage was decreased to 500 mg/h with occasional increases to treat intermittent spasms. The infusion continued to be weaned and finally was stopped on hospital day 27, which represented 20 days of intravenous magnesium treatment. By hospital day 28, the patient was transferred to the medical surgical ward. At this time, the patient could sit up in bed and was able to maintain normal oxygen saturation without supplemental oxygen. Spasms were no longer present. He was neurologically intact with a Glasgow coma score of E4 V1T (intubated) M6. The tracheostomy tube was successfully removed shortly thereafter.

Discussion

In industrialized countries, improved medical services such as standardized immunization regimens and newborn delivery practices have significantly decreased the incidence of tetanus. However, tetanus remains endemic in the developing world. Although the majority of cases occur among neonates, there continues to be significant morbidity and mortality from nonneonatal tetanus in developing countries.² A World Health Organization estimate based on worldwide community-based surveys extrapolated at least 155,000 cases and 78,000 deaths from nonneonatal tetanus in 1990.²

Clostridium tetani is a gram-positive, obligate anaerobic bacillus.³ The toxins secreted by *C tetani* enter the

central nervous system and interfere with inhibitory impulses to motor neurons.^{4,5} Reflex inhibitory arcs are lost, and both agonist and antagonist muscle groups contract simultaneously.⁵ Tetanus also leads to derangements of the autonomic nervous system, including an excessive sympathetic state and increased circulating plasma catecholamines.

The incubation period for tetanus infections averages 7 to 10 days.^{5,6} Shorter incubation periods correlate with a more severe disease course and worse prognosis.^{5,7} The first week of the illness is characterized by muscle rigidity and spasms. Patients may present with trismus or risus sardonicus, attributable to increased tone in the orbicularis oris muscles.^{3,5,6} Spasms then progress to more generalized involvement of the body. Tetanic spasms frequently are provoked by sensory stimuli, and affected patients are very sensitive to visual, tactile, and auditory triggers.⁸ Opisthotonic spasms may occur, which are very painful, generalized tetanic spasms of the body associated with severe arching of the back.^{3,5,8} Airway compromise may occur as a result of a variety of mechanisms, ranging from acute obstruction after laryngeal muscle spasm or decreased chest wall compliance owing to generalized muscle spasms.^{3,6} Autonomic instability typically starts after the spasms and persists for 1 to 2 weeks.⁵ By decreasing the incidence of respiratory complications, modern intensive care has uncovered the degree of autonomic instability that can be associated with tetanus. One study found that with intensive care unit (ICU) treatment, 40% of deaths from tetanus occurred secondary to sudden cardiac death and autonomic instability, whereas 15% of deaths were attributed to respiratory complications. Before the establishment of ICU care in this study, 80% of patients died as a result of acute respiratory failure.⁹

The treatment of tetanus infection includes antibiotic administration, passive immunization with human tetanus immune globulin (TIG), intravenous immune globulin (IVIG), or tetanus antitoxin.^{3,7,10} Affected individuals also must be vaccinated because infection does not provide immunity.^{5,10} As a result of the prolonged time frame of clinical infection, much of the treatment of generalized tetanus infections consists of supportive care such as airway protection, deep sedation, control of autonomic instability and muscle spasms, and artificial ventilation. Common medications used for such goals include benzodiazepines, opiates, and neuromuscular antagonists. Each of these classes of medications has its own associated toxicity. Thus, interest has developed in the use of MgSO_4 infusion as a possible mechanism to replace or reduce the use of sedative or paralytic medications.

The mechanism by which magnesium treatment affects muscle tone and contraction is not well understood. It is

thought that an increased extracellular magnesium concentration blocks neuromuscular transmission by inhibiting acetylcholine release at the motor endplate.¹¹ Magnesium also antagonizes calcium influx at calcium channels, and thus decreases electrical conduction as well as muscle contraction.¹¹ Because of its ability to inhibit acetylcholine release and activity at the neuromuscular junction, magnesium in overdose causes paralysis, sedation, and coma.^{5,12} Excessive magnesium levels can also lead to cardiac conduction abnormalities, hypotension, or bradyarrhythmias.^{5,12} The risk for toxicity is increased in patients with renal insufficiency owing to impaired clearance.¹²

Support for the use of magnesium in the treatment of tetanus is growing in the clinical literature. However, given the low incidence of the disease in developed nations, prospective, randomized clinical trials have been infrequent. In 2006, Thwaites and colleagues¹³ published the only double-blind, randomized, controlled trial regarding the use of magnesium for the treatment of tetanus. Their study of 195 patients suggested that magnesium treatment can decrease the need for additional sedatives and neuromuscular blockade. Furthermore, patients treated with magnesium appeared to have attenuation of the autonomic derangements caused by tetanus.¹³ In another prospective observational study of 40 patients treated with magnesium, 23 patients were able to breathe spontaneously without mechanical support; however, all patients in the study had received a tracheostomy for airway protection before initiation of treatment.¹ The clinical severity and natural progression of tetanus infections can be quite variable, which likely explains the different rates of clinical outcomes seen in the literature.

At the JDWNRH referral hospital in Thimphu, Bhutan, the number of tetanus cases has dropped significantly in recent times with improved access to healthcare. However, tetanus continues to be a challenging disease entity for clinical management. In the last 5 years, the JDWNRH has treated 3 cases of tetanus infection. Except for the case described above, the other 2 patients died. This case demonstrates the great promise of MgSO₄ infusions for the management of severe tetanus infections even in constrained resource settings. For this patient, MgSO₄ treatment greatly minimized the need for high-dose benzodiazepines and prolonged neuromuscular blockade. Our team successfully used serial clinical examinations instead of serum magnesium measurements to titrate MgSO₄ infusion rates. We believe this treatment has the potential to decrease mortality with minimal risk. Further research will help validate whether this strategy could be expanded to other clinical sites with limited medical

resources, precisely the most frequent setting in which severe cases of tetanus will be treated.

Appendix

See Table E1

References

- Attygalle D, Rodrigo N. Magnesium as first line therapy in the management of tetanus: a prospective study of 40 patients. *Anaesthesia*. 2002;57:811–817.
- Galazka A, Birmingham M, Kurian M, Gasse FL. Tetanus. In: Murray CJL, Lopez AD, Mathers CD, eds. *The Global Epidemiology of Infectious Diseases*. Geneva: World Health Organization; 2004:151–199.
- Reddy P, Bleck TP. Clostridium tetani (tetanus). In: Mandell GL, Bennett JE, Dolin R, eds. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2010:3091–3096.
- Rhee P, Nunley MK, Demetriades D, Velmahos G, Doucet JJ. Tetanus and trauma: a review and recommendations. *J Trauma*. 2005;58:1082–1088.
- Cook TM, Protheroe RT, Handel JM. Tetanus: a review of the literature. *Br J Anaesth*. 2001;87:477–487.
- Ceneviva GD, Thomas NJ, Kees-Folts D. Magnesium sulfate for control of muscle rigidity and spasms and avoidance of mechanical ventilation in pediatric tetanus. *Pediatr Crit Care Med*. 2003;4:480–484.
- American Academy of Pediatrics. Tetanus (lockjaw). In: Pickering L, ed. *Red Book: 2009 Report of the Committee on Infectious Diseases*. 28th ed. Available at: <http://aapredbook.aappublications.org.laneproxy.stanford.edu/cgi/content/full/2009/1/3.132>. Accessed January 17, 2012.
- Brook I. Clostridium tetani (tetanus). In: Long SS, Pickering LK, Prober CG, eds. *Principles and Practice of Pediatric Infectious Diseases*. 3rd rev. ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2008:956–959.
- Trujillo MH, Castillo A, España J, Manzo A, Zerpa R. Impact of intensive care management on the prognosis of tetanus. Analysis of 641 cases. *Chest*. 1987;92:63–65.
- Centers for Disease Control and Prevention. Tetanus: Epidemiology and Prevention of Vaccine-Preventable Diseases. Available at: <http://www.cdc.gov/vaccines/pubs/pinkbook/tetanus.html>. Accessed October 26, 2012.
- Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology. *Br J Anaesth*. 1999;83:302–320.
- Meier KH. Magnesium. In: Olson KR, ed. *Poisoning & Drug Overdose*. 6th ed. New York: McGraw-Hill; 2012. Available at: <http://www.accessmedicine.com.laneproxy.stanford.edu/content.aspx?aID=55978086>. Accessed October 26, 2012.
- Thwaites CL, Yen LM, Loan HT, et al. Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. *Lancet*. 2006;368:1436–1443.

Table E1. Intravenous magnesium infusion protocol (adapted from Attygale et al¹)*

To be used for patients with tetanus with generalized muscle rigidity with or without spasms. Patients should be managed in a high-dependency unit or ICU with immediate access to ventilatory support if needed.

1. Give intravenous metronidazole 500 mg 8-hourly for 10 days, toxoid, and antitoxin/immunoglobulin.
2. Perform surgical debridement of the wound, insertion of nasogastric tube, and tracheostomy under general anesthesia as soon as possible.
3. Omit all sedatives.
4. Urine output $>0.5 \text{ mL/kg}^{-1}/\text{h}^{-1}$.
5. Start intravenous magnesium therapy with a loading dose of 70 mg/kg over 30 minutes and maintenance dose of 2 g/h if <60 years and 1 g/h if >60 years or moderate tetanus (no spasms). Titrate to the control of spasms or degree of rigidity that is acceptable to the patient.
 - a. Increase dose by 0.5 g (<60 years) or 0.25 g (>60 years) 6-hourly until spasms are controlled, even if patellar reflex is suppressed or respiratory inadequacy occurs.
 - b. Reduce the dose by 0.25 g/h once control of spasms is established to ensure that the minimum effective dose is being given.
6. Monitor:
 - a. hourly urine output.
 - b. ability to cough, patellar reflex, respiratory rate, tidal volume, [arterial blood gases] and chest x-ray if indicated.
 - c. noninvasive blood pressure, electrocardiogram (ECG), pulse oximetry, [12-lead ECG every third day (or daily if magnesium concentrations exceed therapeutic levels)].
 - d. sedation score.
 - e. [serum magnesium daily, more frequently if signs of toxicity].
 - f. clinical signs of hypocalcaemia, [serum calcium every third day and x-ray of hand before and after therapy].
7. Interventions:
 - a. if respiratory rate is >30 breaths/min or the tidal volume is $<4 \text{ mL/kg}$, support ventilation, give chest physiotherapy, and provide bronchial toilet.
 - b. if hypotensive ($<70 \text{ mm Hg}$ systolic), stimulate patient, and if bradycardic (<40 beats/min), give atropine.
 - c. if unresponsive, [send blood for serum magnesium level], stop magnesium, and give intravenous calcium gluconate.
 - d. when stable, continue at a lower dose. If spasms recur, supplement with relaxants and ventilatory support.
 - e. if blood pressure is $>170 \text{ mm Hg}$ systolic or heart rate >120 beats/min for >1 hour, give intravenous morphine.
 - f. attempt weaning from magnesium therapy in the third week.

*The parts of the protocol that we did not or were not able to follow because of a lack of resources are indicated by enclosing them in square brackets.